Autolus Therapeutics (AUTL) Depreciation & Amortization (IS) (2019 - 2023)

Autolus Therapeutics (AUTL) has 5 years of Depreciation & Amortization (IS) data on file, last reported at $1.4 million in Q3 2023.

• For the quarter ending Q3 2023, Depreciation & Amortization (IS) fell 22.83% year-over-year to $1.4 million; the trailing twelve-month figure through Sep 2023 stood at $6.6 million (down 20.0% YoY), and the FY2019 full-year result was $3.3 million, changed N/A from the prior year.
• Depreciation & Amortization (IS) for Q3 2023 stood at $1.4 million, down from $1.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (IS) topped out at $2.4 million in Q3 2021 and bottomed at $1.3 million in Q1 2020.
• The 5-year median for Depreciation & Amortization (IS) is $1.7 million (2021), against an average of $1.8 million.
• The widest annual swing landed in 2020, when Depreciation & Amortization (IS) plunged 41.88%; it then surged 77.11% in 2021.
• A 5-year view of Depreciation & Amortization (IS) shows it stood at $2.2 million in 2019, then plunged by 32.66% to $1.5 million in 2020, then surged by 66.76% to $2.4 million in 2021, then slipped by 27.0% to $1.8 million in 2022, then decreased by 22.83% to $1.4 million in 2023.
• The last three Depreciation & Amortization (IS) figures came in at $1.4 million (Q3 2023), $1.5 million (Q2 2023), and $1.9 million (Q1 2023), per Business Quant data.

Peer Comparison